GOLDMAN SACHS GROUP INC - ALLOGENE THERAPEUTICS INC ownership

ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 164 filers reported holding ALLOGENE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 2.03 and the average weighting 0.2%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of ALLOGENE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$4,463,221
-40.1%
1,407,956
-6.1%
0.00%
-50.0%
Q2 2023$7,454,861
+30.7%
1,499,972
+29.9%
0.00%
+100.0%
Q1 2023$5,703,354
-44.0%
1,154,525
-28.7%
0.00%
-50.0%
Q4 2022$10,178,006
-60.7%
1,618,125
-32.6%
0.00%
-66.7%
Q3 2022$25,916,000
+15.1%
2,399,583
+21.5%
0.01%
+20.0%
Q2 2022$22,514,000
-16.6%
1,974,957
-33.3%
0.01%
-16.7%
Q1 2022$26,986,000
-0.8%
2,962,209
+62.5%
0.01%
+20.0%
Q4 2021$27,203,000
-46.5%
1,823,265
-7.9%
0.01%
-54.5%
Q3 2021$50,878,000
+13.7%
1,979,712
+15.4%
0.01%
+10.0%
Q2 2021$44,737,000
-1.1%
1,715,387
+33.9%
0.01%
-9.1%
Q1 2021$45,222,000
+28.9%
1,281,078
-7.8%
0.01%
+22.2%
Q4 2020$35,075,000
+0.3%
1,389,666
+49.9%
0.01%0.0%
Q3 2020$34,955,000
+136.3%
926,950
+168.3%
0.01%
+80.0%
Q2 2020$14,793,000
+307.5%
345,467
+85.0%
0.01%
+400.0%
Q1 2020$3,630,000
-20.2%
186,728
+6.6%
0.00%0.0%
Q4 2019$4,550,000
+58.6%
175,134
+66.4%
0.00%0.0%
Q3 2019$2,868,000
+35.6%
105,246
+33.6%
0.00%0.0%
Q2 2019$2,115,000
+15.8%
78,772
+24.6%
0.00%0.0%
Q1 2019$1,827,000
+10.7%
63,211
+3.1%
0.00%0.0%
Q4 2018$1,650,00061,2870.00%
Other shareholders
ALLOGENE THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Vida Ventures Advisors, LLC 1,798,163$45,386,0009.32%
TPG Group Holdings (SBS) Advisors, Inc. 18,716,306$472,400,0005.23%
Wildcat Capital Management, LLC 1,515,524$38,252,0004.81%
REGENTS OF THE UNIVERSITY OF CALIFORNIA 900,143$22,720,0003.28%
Coastal Bridge Advisors, LLC 385,824$9,738,0001.93%
Casdin Capital, LLC 945,000$23,852,0000.71%
DSAM Partners (London) Ltd 208,798$5,270,0000.62%
BAINCO INTERNATIONAL INVESTORS 152,839$3,858,0000.44%
Pier Capital, LLC 152,071$3,838,0000.41%
Woodline Partners LP 567,539$14,325,0000.38%
View complete list of ALLOGENE THERAPEUTICS INC shareholders